Stock GVBL6 GENOMIC VALLEY BIOTECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomic Valley Biotech Limited

Equities

GVBL6

INE574D01010

Market Closed - Bombay S.E.
Other stock markets
 04:45:48 01/07/2024 BST 		5-day change 1st Jan Change
63.93 INR +4.49% Intraday chart for Genomic Valley Biotech Limited +17.02% +70.75%
05-09 Genomic Valley Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
02-14 Genomic Valley Biotech Limited Announces Appointment of Mrs. Parul Agrawal as an Additional Non-Executive (Non-Independent) Director on the Board with Effect from February 14, 2024 CI

Valuation

Fiscal Period: März 2020 2021 2022 2023
Capitalization 1 26.45 72.09 75.6 66.44
Enterprise Value (EV) 1 40.86 87.44 75.57 66.02
P/E ratio 9.21 x -12.9 x -825 x 10.3 x
Yield - - - -
Capitalization / Revenue 3.12 x 34.6 x 107 x 2.44 x
EV / Revenue 4.83 x 42 x 107 x 2.43 x
EV / EBITDA 7.27 x -65.2 x -20.3 x 7.51 x
EV / FCF 10.6 x -6.31 x -4.05 x -38.8 x
FCF Yield 9.4% -15.9% -24.7% -2.58%
Price to Book 0.52 x 1.61 x 2.63 x 1.88 x
Nbr of stocks (in thousands) 3,055 3,055 3,055 3,055
Reference price 2 8.660 23.60 24.75 21.75
Announcement Date 07/12/20 07/12/21 06/12/22 07/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 5.944 9.85 8.466 2.081 0.7056 27.23
EBITDA 1 1.039 4.276 5.62 -1.341 -3.721 8.788
EBIT 1 0.2813 2.339 3.834 -3.233 -4.564 8.709
Operating Margin 4.73% 23.74% 45.29% -155.37% -646.85% 31.99%
Earnings before Tax (EBT) 1 0.5859 2.347 2.057 -5.018 -0.0165 6.489
Net income 1 0.3409 2.325 2.86 -5.591 -0.0934 6.483
Net margin 5.73% 23.6% 33.78% -268.67% -13.24% 23.81%
EPS 2 0.1100 0.7600 0.9400 -1.830 -0.0300 2.120
Free Cash Flow 1 -1.672 -11.2 3.842 -13.86 -18.67 -1.701
FCF margin -28.13% -113.67% 45.38% -666.29% -2,646.16% -6.25%
FCF Conversion (EBITDA) - - 68.36% - - -
FCF Conversion (Net income) - - 134.33% - - -
Dividend per Share - - - - - -
Announcement Date 04/09/18 31/07/19 07/12/20 07/12/21 06/12/22 07/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net Debt 1 7.39 14 14.4 15.4 - -
Net Cash position 1 - - - - 0.03 0.41
Leverage (Debt/EBITDA) 7.113 x 3.283 x 2.564 x -11.45 x - -
Free Cash Flow 1 -1.67 -11.2 3.84 -13.9 -18.7 -1.7
ROE (net income / shareholders' equity) 0.76% 5.01% 5.83% -11.7% -0.25% 20.2%
ROA (Net income/ Total Assets) 0.28% 2.11% 3.16% -2.59% -5% 13.2%
Assets 1 123.2 110.2 90.6 216.2 1.869 48.94
Book Value Per Share 2 14.80 15.60 16.50 14.70 9.420 11.50
Cash Flow per Share 2 0.0100 0.2500 0.1200 0.0400 0.0100 0.1400
Capex 1 9.43 - 4.77 15.8 - -
Capex / Sales 158.59% - 56.33% 758.99% - -
Announcement Date 04/09/18 31/07/19 07/12/20 07/12/21 06/12/22 07/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. GVBL6 Stock
  4. Financials Genomic Valley Biotech Limited